obicetrapib
Sponsor Newamsterdam Pharma CO N.V. · listed as NAMS
obicetrapib is a drug asset sponsored by Newamsterdam Pharma CO N.V., listed as NAMS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 2026 (month precision, medium confidence), tied to trial NCT05202509. That trial is in Phase 3 and currently active not recruiting, studying Atherosclerotic Cardiovascular Disease. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Other tracked assets in the same trials — NCT07219602: obicetrapib ezetimibe.
Trials for obicetrapib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05202509 catalyst | Phase 3 | Active, not recruiting | 2026-11 | Experimental | NewAmsterdam Pharma | Atherosclerotic Cardiovascular Disease |
| NCT07219602 | Phase 3 | Active, not recruiting | 2028-03 | Experimental | NewAmsterdam Pharma | Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More NAMS catalysts